spacer
home > news
INDUSTRY NEWS AND PRESS RELEASES

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

Acquisition increases BioIVT’s supply of leukopaks, plasma and sera, and enhances its ability to support the in vitro diagnostic market

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community for more than 37 years. BSC is headquartered in Colmar, PA, with two additional FDA-registered donor centers in Allentown, PA and Reading, PA. More>>

 
phone +1 516 483 1196
email customerservice@bioivt.com
web www.bioivt.com/
email PO Box 770, Hicksville, NY, 11802-0770
 

Charles River to Present Collaborative Methods at Neuroscience 2018

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 80 countries, will take place from November 3-7, in San Diego, California. More>>

 
phone +1.877.CRIVER.1
email askcharlesriver@crl.com
web www.criver.com
email Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887
 

Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

New partnership allows Charles River’s clients access to Distributed Bio’s antibody discovery platforms

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms. More>>

 
phone +1.877.CRIVER.1
email askcharlesriver@crl.com
web www.criver.com
email Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887
 

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVT’s commercial activities, including global sales, marketing and customer service. More>>

 
phone +1 516 483 1196
email customerservice@bioivt.com
web www.bioivt.com/
email PO Box 770, Hicksville, NY, 11802-0770
 

Change of Company Name: VTU Technology is now VALIDOGEN

UNLOCK PICHIA – A technology from VALIDOGEN

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH. More>>

 
phone +43 316 4009 4000
email office@validogen.com
web www.validogen.com/
email VALIDOGEN GmbH, Parkring 18, 8074 Raaba-Grambach
 
spacer
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>


White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

Industry Events

Pharma Packaging and Labelling East Coast 2019

20-21 February 2019, Phildaelphia, USA

Now in its 11th year, Pharma Packaging and Labeling is back to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labeling chain with both maximum efficiency and minimal cost.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement